Back to top
more

Precision BioSciences (DTIL)

(Delayed Data from NSDQ)

$9.38 USD

9.38
28,458

-0.34 (-3.50%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $9.45 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

by Zacks Equity Research

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -82.61% and 14.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -46.30% and 93.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

by Zacks Equity Research

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 56.52% and 200.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of -12.06% and 4.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 76.32% and 12.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos

by Zacks Equity Research

Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.

Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

by Zacks Equity Research

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?